UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?

Value in health, 2016-07, Vol.19 (5), p.525-530

Drummond, Michael, PhD

2016

Link zum Volltext

Verfügbarkeit prüfen

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

Value in health, 2013-03, Vol.16 (2), p.231-250

2013

Link zum Volltext

Verfügbarkeit prüfen

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

Value in health, 2013-03, Vol.16 (2), p.e1-e5

2013

Link zum Volltext

Verfügbarkeit prüfen

Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward

Value in health, 2017-03, Vol.20 (3), p.487-495

2017

Link zum Volltext

Verfügbarkeit prüfen

Economic Evaluation for Devices and Drugs—Same or Different?

Value in health, 2009-06, Vol.12 (4), p.402-404

2009

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Added Value of Health Technologies: Reconciling Different Perspectives

Value in health, 2013-01, Vol.16 (1), p.S7-S13

2013

Link zum Volltext

Verfügbarkeit prüfen

Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation

Value in health, 2014-09, Vol.17 (6), p.707-713

2014

Link zum Volltext

Verfügbarkeit prüfen

What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?

Value in health, 2010-12, Vol.13 (8), p.1028-1037

2010

Link zum Volltext

Verfügbarkeit prüfen

Open Access Publication in Value in Health

Value in health, 2016-06, Vol.19 (4), p.297-297

2016

Link zum Volltext

Verfügbarkeit prüfen

Retaining, and Enhancing, the QALY

Value in health, 2009-03, Vol.12 (s1), p.S18-S26

2009

Link zum Volltext

Verfügbarkeit prüfen

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

Value in health, 2010, Vol.13 (1), p.3-7

2010

Link zum Volltext

Verfügbarkeit prüfen

Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom

Value in health, 2009-06, Vol.12, p.S8-S13

2009

Link zum Volltext

Verfügbarkeit prüfen

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

Clinical therapeutics, 2013-04, Vol.35 (4), p.356-363

2013

Link zum Volltext

Verfügbarkeit prüfen

The Role of Economic Evaluation in Meeting IOM’s Recommendations on Delivering High-Quality Cancer Care

Value in health, 2014-07, Vol.17 (5), p.497-500

2014

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Coverage Decisions: The Need for a Reality Check

Value in health, 2007-09, Vol.10 (5), p.321-321

Drummond, Michael, PhD

2007

Link zum Volltext

Verfügbarkeit prüfen

The Use and Performance of Productivity Scales to Evaluate Presenteeism in Mood Disorders

Value in health, 2012-12, Vol.15 (8), p.1148-1161

2012

Link zum Volltext

Verfügbarkeit prüfen

Implementing Pharmacoeconomic Guidelines in Latin America: Lessons Learned

Value in health, 2011-07, Vol.14 (5), p.S3-S7

2011

Link zum Volltext

Verfügbarkeit prüfen

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI

Value in health, 2010, Vol.13 (1), p.28-33

2010

Link zum Volltext

Verfügbarkeit prüfen

Letter from the Editors

Value in health, 2012, Vol.15 (6), p.791-791

2012

Link zum Volltext

Verfügbarkeit prüfen

Improving the Quality of Papers Published in Pharmacoeconomics and Outcomes Research

Value in health, 2013-03, Vol.16 (2), p.229-230

2013

Link zum Volltext

Verfügbarkeit prüfen

Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study

Value in health, 2007-07, Vol.10 (4), p.238-246

2007

Link zum Volltext

Verfügbarkeit prüfen

Health and climate change: policy responses to protect public health

The Lancet (British edition), 2015-11, Vol.386 (10006), p.1861-1914

2015

Link zum Volltext

Verfügbarkeit prüfen

The Lancet Countdown: tracking progress on health and climate change

The Lancet (British edition), 2017-03, Vol.389 (10074), p.1151-1164

2017

Link zum Volltext

Verfügbarkeit prüfen

Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

Value in health, 2009-06, Vol.12 (4), p.409-418

2009

Link zum Volltext

Verfügbarkeit prüfen

Validating the 8 CPCSSN Case Definitions for Chronic Disease Surveillance in a Primary Care Database of Electronic Health Records

Annals of family medicine, 2014-07, Vol.12 (4), p.367-372

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Englisch
(38)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward

Economic Evaluation for Devices and Drugs—Same or Different?

Assessing the Added Value of Health Technologies: Reconciling Different Perspectives

Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation

What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?

Open Access Publication in Value in Health

Retaining, and Enhancing, the QALY

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

The Role of Economic Evaluation in Meeting IOM’s Recommendations on Delivering High-Quality Cancer Care

Evidence for Coverage Decisions: The Need for a Reality Check

The Use and Performance of Productivity Scales to Evaluate Presenteeism in Mood Disorders

Implementing Pharmacoeconomic Guidelines in Latin America: Lessons Learned

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI

Letter from the Editors

Improving the Quality of Papers Published in Pharmacoeconomics and Outcomes Research

Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study

Health and climate change: policy responses to protect public health

The Lancet Countdown: tracking progress on health and climate change

Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

Validating the 8 CPCSSN Case Definitions for Chronic Disease Surveillance in a Primary Care Database of Electronic Health Records

Suchergebnisse filtern